0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Electron Therapy for Orbital and Periorbital Lesions Using Customized Lead Eye Shields

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose: To establish the protective efficacy against late complications of electron therapy using customized lead eye shields in cases with orbital and periorbital lesions. Methods: Between 1982 and 2006, 16 patients with 22 orbital and periorbital lesions were treated by electron therapy. Customized lead eye shields were prepared and placed in the respective patients’ eyes during each fraction of electron therapy. The toxicity and local control rates were analyzed. Results: The preparation period for the customized lead eye shields was 2 days. The shields could be used throughout the treatment period in all the patients. No evidence of radiation cataract was observed in 15 of the 16 patients. None of the patients developed corneal ulceration or evidence of lead poisoning. Conclusion: Customized lead eye shields could be made relatively quickly, and electron therapy for orbital and periorbital lesions could be undertaken safely without any late complication.

          Related collections

          Most cited references 5

          • Record: found
          • Abstract: not found
          • Article: not found

          Curative radiotherapy for primary orbital lymphoma

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma.

            This paper describes the results of radiotherapy in early stage orbital non-Hodgkin's lymphoma. From 1970 to 1985, 33 orbital localizations in 30 patients were treated. The total dose applied ranged from 21 to 57 Gy (2 Gy per fraction), two-thirds of all patients received a dose of 40 Gy. The complete-response rate was 94% and the 10 years actuarial survival was 90%; no significant difference in survival was observed between patients with low grade or intermediate grade lymphoma. No local recurrence was detected during follow up and 20% of the patients developed generalized disease. Two optic nerve neuropathies and three retinopathies were observed in five patients, four of these occurred at a dose level of less than 43 Gy. Keratitis occurred in 58% of the patients treated, a sicca syndrome in 30% and cataract of different grades in 58% of the patients treated. Although local control was excellent, severe complications were observed in 13% of the patients who received a dose of less than 43 Gy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Role of radiotherapy for primary orbital lymphoma.

               Kwon Park,  C. Suh,  G. Yang (2002)
              To define the role of radiation therapy of primary orbital lymphoma, a retrospective analysis was undertaken for 18 patients with primary orbital lymphoma who were treated with curative radiotherapy between 1984 and 1995. The histology was found to be low grade lymphoma in 11 patients, intermediate grade in 7. All patients were of Ann Arbor stage IE, but bilateral involvement of the orbit was observed in 3 patients (16.6%). Anatomical subsites involved were the retrobulbar, eyelid, and conjunctiva in eight, five, and four patients, respectively. The median radiation dose was 30 Gy ranging from 20 Gy to 50 Gy. Twelve of 18 patients received a radiation dose of 30 Gy or less. To properly protect the lens during irradiation, the contact lens blocks were used for nine patients with conjunctival and eyelid tumor or the hanging eye bar blocks were applied for eight patients with retrobulbar tumor. Chemotherapy was given for seven patients with intermediate-grade malignant lymphoma. Two patients had been treated by surgery before referral.
                Bookmark

                Author and article information

                Journal
                OPH
                Ophthalmologica
                10.1159/issn.0030-3755
                Ophthalmologica
                S. Karger AG
                0030-3755
                1423-0267
                2009
                February 2009
                26 November 2008
                : 223
                : 2
                : 96-101
                Affiliations
                aDepartment of Radiology, Section of Diagnostic Radiology and Oncology, bDepartment of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University, and cDepartment of Radiotherapy, National Cancer Center Hospital, Tokyo, dDepartment of Radiology, Niigata Cancer Center Hospital, Niigata, Japan
                Article
                176190 PMC2790777 Ophthalmologica 2009;223:96–101
                10.1159/000176190
                PMC2790777
                19033716
                © 2008 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 4, Tables: 3, References: 21, Pages: 6
                Categories
                Original Paper

                Comments

                Comment on this article